Last reviewed · How we verify
BGB-A425
At a glance
| Generic name | BGB-A425 |
|---|---|
| Also known as | Surzebiclimab |
| Sponsor | BeiGene |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (PHASE3)
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (PHASE2)
- Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BGB-A425 CI brief — competitive landscape report
- BGB-A425 updates RSS · CI watch RSS
- BeiGene portfolio CI